Pfizer Inc, one of the world's premier innovative biopharmaceutical companies, announced that the US Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to company's pending acquisition of Hospira.
In addition, Pfizer announced that Brazil’s Superintendency-General of CADE has published its unconditional clearance decision. The FTC’s clearance is contingent upon Pfizer’s commitment to divest four US sterile injectable assets, including Acetylcysteine, Clindamycin, Voriconazole and Melphalan.
“We now look forward to combining our two companies and expect the transaction to close in early September” said Ian Read, chairman and chief executive officer, Pfizer.
Subscribe to PharmaTutor News Alerts by Email >>
